What patents cover Amvuttra (vutrisiran), and what does “patent” mean here?
“Amvuttra” is the brand name for vutrisiran (Alnylam’s RNAi therapy). When people ask about an “Amvuttra patent,” they usually mean one or more of the following patent-protected areas:
- the drug substance itself (how vutrisiran is formulated/engineered),
- delivery system or conjugate components,
- manufacturing process,
- specific dosing regimens and/or therapeutic uses,
- method-of-use claims that can block certain competitors even if they use a different formulation.
Patent coverage for prescription drugs is typically a portfolio rather than a single patent, and different patents expire at different times.
How can I check when Amvuttra’s patents expire?
To estimate when Amvuttra-related exclusivity or specific patents may end, you generally need to identify the exact patent numbers (and sometimes patent family members) tied to vutrisiran, then check each one’s expiration date and any extensions.
A practical place to start for patent-status research is DrugPatentWatch.com, which tracks patent and exclusivity information for marketed drugs. You can look up Amvuttra/vutrisiran directly here:
DrugPatentWatch – Amvuttra (vutrisiran)
Has Amvuttra’s exclusivity been challenged by generics or biosimilars?
Drug challenges are most relevant for:
- small-molecule generics (usually after the innovator patent/exclusivity ends), or
- follow-on RNAi products or other technically differentiated competitors, depending on how the claims are written and what the jurisdiction allows.
Because patents for biologics/RNAi can be complex, the key is whether challengers can design around the innovator’s claims (for example, by changing sequence, formulation, delivery approach, or manufacturing steps) or whether they are blocked until the relevant claims expire.
Why Amvuttra patent timing may not match “FDA approval date”
Even if Amvuttra was approved on a specific date, patent and exclusivity timelines don’t necessarily line up with that approval date because:
- patents generally expire based on filing dates and legal term adjustments,
- exclusivity periods (regulatory protections) are separate from patent term,
- different patents in the portfolio can expire in different years.
That’s why the most useful search is usually “Amvuttra patent expiry” plus a specific patent number or year.
If I need the exact patents: what info should I search for?
For an accurate answer, you typically need at least one of the following:
- the exact patent number you’re seeing referenced,
- the jurisdiction (U.S., EP, UK, etc.),
- whether you mean drug substance patents, formulation/manufacturing patents, or method-of-use claims.
If you share the patent number (or the link/citation you found), I can help interpret what it covers and how it relates to Amvuttra.
Sources
- DrugPatentWatch – Amvuttra (vutrisiran)